Phibro Animal Health (PAHC) shares soared 10.2% in the last trading session to close at $20.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% gain over the past four weeks. Phibro scored a strong price increase, on investors' optimism driven by its impending fiscal fourth-quarter 2024 financial results, which is slated to be released on Aug 28 post the closing bell. The Zacks Consensus Estimate for the fourth quarter revenue ...

The upcoming report from Phibro Animal Health (PAHC) is expected to reveal quarterly earnings of $0.34 per share, indicating a decline of 10.5% compared to the year-ago period. Analysts forecast revenues of $262.44 million, representing an increase of 2.9% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Prior to a comp ...

Phibro Animal Health (PAHC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 28, 2024, might help the stock move higher if these key numbers are better ...

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Revisions for Phibro Bottom Line The upgrade of Phibro to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. One company to watch right now is Phibro Animal Health (PAHC) . PAHC is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 12.62, which compares to its ind ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely o ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being un ...

Have you looked into how Phibro Animal Health (PAHC) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this maker of animal health products and nutritional supplements, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall fin ...

财务数据和关键指标变化 - 公司第三季度总销售额增长7%,调整后EBITDA和调整后净收入均增长9% [25][28][29] - 动物保健业务销售额增长10%,其中疫苗销售增长26%,MFA和其他业务增长16%,但营养特产品销售下降11% [31][32][33] - 矿物营养和性能产品业务销售有所改善,但仍有下降 [34][35] - 年初至今,公司总收入增长3%,调整后EBITDA下降3% [19][20] 公司战略和发展方向 - 公司宣布收购Zoetis的MFA业务,将增强公司的物种和产品组合,提高盈利能力和偿债能力 [13][14][15][21][22] - 公司将继续投资于增长较快的疫苗、营养特产品和宠物产品业务 [15][53][60] - 公司将通过偿还债务来降低财务杠杆,并保持现有的股息政策 [54][55][56] 管理层对经营环境和未来前景的评论 - 公司对动物保健业务的持续增长以及矿物营养和性能产品业务的改善持乐观态度 [16][40] - 公司确认了2024财年的收入、调整后EBITDA和调整后每股收益的指引 [38][39] 行业竞争 - 公司收购Zoetis的MFA业务将增强其在无抗生素饲料添加剂市场的竞争力 [61][62]

Phibro Animal Health Corporation Webcast and Conference Call May 9, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2024 Third Quarter Ended March 31, 2024 May 9, 2024 Important Information Cautionary Statement Regarding Forward-Looking Statements Non-GAAP Financial Measures We use non-GAAP financial measures, such as adjusted EBITDA and adjusted net income, to assess and analyze our operational results and trends and to make financ ...